The influence of ApoE4 on clinical progression of dementia: A meta-analysis

International Journal of Geriatric Psychiatry

Volumn 26, Issue 5, 2011, Pages 520-526

  Allan, Charlotte L ^a   Ebmeier, Klaus P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apolipoproteins; Cognition; Dementia; Genetics; Meta analysis; Systematic review

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ARTICLE; CASE CONTROL STUDY; COGNITIVE DEFECT; COHORT ANALYSIS; DEMENTIA; DISEASE COURSE; DISEASE DURATION; EFFECT SIZE; EMBASE; GENETIC RISK; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; MEDLINE; MENTAL DETERIORATION; META ANALYSIS (TOPIC); MORTALITY; OUTCOME ASSESSMENT; SAMPLE SIZE;

APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; DEMENTIA; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK FACTORS;

EID: 79953239431     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2559     Document Type: Article

References (35)

1. Avramopoulos D. 2009. Genetics of Alzheimer's disease: recent advances. Genome Med 1: 34.
2. Bales KR, Verina T, Cummins DJ, et al. 1999. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 96: 15233-15238. (Pubitemid 30019795)
3. Basun H, Grut M, Winblad B, et al. 1995. Apolipoprotein epsilon 4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci Lett 183: 32-34.
4. Bertram L, McQueen MB, Mullin K, et al. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39: 17-23. (Pubitemid 46026496)
5. Biostat. 2006. Comprehensive Meta-Analysis 2.2.048, Copyright ©. Englewood, NJ, USA.
6. Buckner RL. 2004. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44: 195-208. (Pubitemid 39348840)
7. Chai CK. 2007. The genetics of Alzheimer's disease. Am J Alzheimer's Dis Other Demen 22: 37-41. (Pubitemid 46339249)
8. Chalmers K, Wilcock GK, Love S. 2003. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathol Appl Neurobiol 29: 231-238. (Pubitemid 36718171)
9. Corder EH, Saunders AM, Strittmatter WJ, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
10. Craft S, Teri L, Edland SD, et al. 1998. Accelerated decline in apolipoprotein E-epsilon homozygotes with Alzheimer's disease. Neurology 51: 149-153. (Pubitemid 28345375)
11. Dal Forno G, Rasmusson DX, Brandt J, et al. 1996. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 53: 345-350. (Pubitemid 26110090)
12. Dal Forno G, Carson KA, Brookmeyer R, et al. 2002. APOE genotype and survival in men and women with Alzheimer's disease. Neurology 58: 1045-1050. (Pubitemid 34298543)
13. Farrer LA, Cupples LA, Haines JL, et al. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349-1356.
14. Forstl H, Sattel H, Sarochan M, et al. 1996. The course of Alzheimer's disease and normal aging: Results from a prospective multidimensional study. Nervenarzt 67: 730-738.
15. Frisoni GB, Govoni S, Geroldi C, et al. 1995. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 37: 596-604.
16. Hartman RE, Laurer H, Longhi L, et al. 2002. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci 22: 10083-10087. (Pubitemid 35416846)
17. Hawi Z, Sheehan K, Lynch A, et al. 2003. Late onset Alzheimer's disease and apolipoprotein association in the Irish population: relative risk and attributable fraction. Ir J Med Sci 172: 74-76. (Pubitemid 36987419)
18. Herholz K, Nordberg A, Salmon E, et al. 1999. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 10: 494-504. (Pubitemid 29512018)
19. Hirono N, Hashimoto M, Yasuda M, et al. 2003. Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon4 allele. J Neuropsychiatry Clin Neurosci 15: 354-358. (Pubitemid 36999379)
20. Holmes C, Levy R, McLoughlin DM, et al. 1996. Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 61: 580-583. (Pubitemid 27023334)
21. Jonker C, Schmand B, Lindeboom J, Havekes LM, Launer LJ. 1998. Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 55: 1065-1069. (Pubitemid 28367231)
22. Juva K, Verkkoniemi A, Viramo P, et al. 2000. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 54: 412-415. (Pubitemid 30078074)
23. Kanai M, Shizuka M, Urakami K, et al. 1999. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 267: 65-68. (Pubitemid 29251624)
24. Kim JM, Shin IS, Yoon JS. 2002. Apolipoprotein E among Korean Alzheimer's disease patients in community-dwelling and hospitalized elderly samples. Dement Geriatr Cogn Disord 13: 119-124.
25. Kleiman T, Zdanys K, Black B, et al. 2006. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord 22: 73-82.
26. Kurz A, Egensperger R, Haupt M, et al. 1996. Apolipoprotein E epsilon4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 47: 440-443. (Pubitemid 26324040)
27. Lanterna LA, Ruigrok Y, Alexander S, et al. 2007. Meta-analysis of APOE genotype and subarachnoid hemorrhage: clinical outcome and delayed ischemia. Neurology 69: 766-775. (Pubitemid 47300934)
28. Lehtovirta M, Kuikka J, Helisalmi S, et al. 1998. Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 64: 742-746. (Pubitemid 28274407)
29. Mori E, Lee K, Yasuda M, et al. 2002. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 51: 209-214. (Pubitemid 34111443)
30. Nagy Z, Esiri MM, Jobst KA, et al. 1995. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 69: 757-761.
31. Polvikoski T, Sulkava R, Haltia M, et al. 1995. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333: 1242-1247.
32. Stern Y, Brandt J, Albert M, et al. 1997. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 41: 615-620. (Pubitemid 27212655)
33. Strittmatter WJ, Saunders AM, Schmechel D, et al. 1993. Apolipoprotein E: highavidity binding to beta-amyloid and increased frequency of type 4 allele in lateonset familial Alzheimer disease. Proc Natl Acad Sci U S A 90: 1977-1981.
34. von Elm E, Altman DG, Egger M, et al. 2007. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4: e296.
35. Zhou W, Xu D, Peng X, et al. 2008. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma 25: 279-290. (Pubitemid 351457767)